Multiple Myeloma Discussions

CC-98633-MM-001, Atalanta-1, KarMMa-2 Cohort 2a, CARTITUDE-2 Cohort B, CC‑95266‑MM‑001

ASH 2022

CAR-T cells - manufacturing, earlier lines & new…

M. Merz, F. Schjesvold, B. C. Lipe, H. Einsele

Ascent Trial, GEM-CESAR

ASH 2022

Asymptomatic myeloma - what do we really want to…

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel

Magnetismm-3, MajesTEC-2, GO39775

ASH 2022

Bispecific antibodies - consolidating data, clinical…

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel, H. Einsele

GMMG-Concept, UK OPTIMUM/MUKnine Trial, Myeloma XI, RADAR UK-MRA Myeloma XV

ASH 2022

Treatment of high-risk NDMM patients and MRD-driven…

M. Merz, F. Schjesvold, B. C. Lipe, K. Weisel

CLL and Lymphoma Discussions

ALPINE, BRUIN

ASH 2022

Zanu with superior PFS, Pirtobrutinib Update in R/R…

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

ELM-2, FLIPI24

ASH 2022

When to treat or not? Watch and wait!? Bispecifics or…

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

Alycante, ZUMA-7

ASH 2022

Glofi - RCHOP in 1st line, Axi-Cel in 2nd line, TMTV…

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

TRIANGLE, TARMAC

ASH 2022

Do we treat all MCL identically? New data on Ibru,…

M. Dreyling, A. Niebla, C. Thieblemont, S. Ferrero, T. Eyre

Newly Diagnosed Multiple Myeloma

ASH 2022

NDMM highlights

C. Ola Landgren, MD

MRD2STOP, GEM2014MAIN, RADAR

ASH 2022

Establish MRI diagnostics early

Maximilian Merz, MD

GMMG-Concept

ASH 2022

Quadruplet for newly diagnosed high-risk patients

Katja Weisel, MD

Myeloma XI

ASH 2022

Maintenance with lenalidomide - how long?

Maximilian Merz, MD

DSMM XIII

ASH 2022

To transplant or not?

Brea C. Lipe, MD

Newly Diagnosed Multiple Myeloma - Multilanguage

ASH 2022

NDMM highlights

C. Ola Landgren, MD

MRD2STOP, GEM2014MAIN, RADAR

ASH 2022

MRD-Diagnostik früh etablieren

Maximilian Merz, MD

GMMG-Concept

ASH 2022

Isa-KRd bei HR NDMM: Hohe MRD Negativität

Katja Weisel, MD

IFM2017-03

ASH 2022

Kortikoid-Einsparung bei unfitten Patienten unter DR

Hermann Einsele, MD

Myeloma XI

ASH 2022

Erhaltung mit Lenalidomid - wie lange?

Maximilian Merz, MD

Relapsed/Refractory Multiple Myeloma

ASH 2022

Bispecific antibodies highlights

C. Ola Landgren, MD

MonumenTAL-1

ASH 2022

GPRC5D-immunotherapy

Fredrik Schjesvold, MD

GO39775

ASH 2022

Bispecific antibodies

Fredrik Schjesvold, MD

ASH 2022

More treatment options with bispecifics emerging!

Hermann Einsele, MD

Nex-T CAR-T

ASH 2022

New generation CAR-T cell therapy with fast…

Katja Weisel, MD

MonumenTAL-1

ASH 2022

Still biting, Talquetamab?

Brea C. Lipe, MD

ASH 2022

CAR-T cells: new targets and early treatment

Hermann Einsele, MD

NEX-T CAR-T, Atalanta-1

ASH 2022

New CAR-T technologies

Fredrik Schjesvold, MD

MajesTEC-2, KarMMa-2 Cohort 2a

ASH 2022

The future of immunotherapy

Maximilian Merz, MD

Relapsed/Refractory Multiple Myeloma - Multilanguage

ASH 2022

Bispecific antibodies highlights

C. Ola Landgren, MD

MonumenTAL-1

ASH 2022

GPRC5D immunterapi

Fredrik Schjesvold, MD

MajesTEC-2, KarMMa-2 Cohort 2a

ASH 2022

Die Zukunft der Immuntherapie

Maximilian Merz, MD

ASH 2022

CAR-T Zellen: Neue erfolgsversprechende Targets und…

Hermann Einsele, MD

NEX-T CAR-T, Atalanta-1

ASH 2022

Nye CAR-T-teknologier

Fredrik Schjesvold, MD

ASH 2022

Bispezifische Antikörper: Weitere Behandlungsoptionen…

Hermann Einsele, MD

Nex-T CAR-T

ASH 2022

Neue Generation der CAR-T Zelltherapie mit schneller…

Katja Weisel, MD

GO39775

ASH 2022

Bispesifikke antistoffer

Fredrik Schjesvold, MD

Smoldering Myeloma/MGUS

ASH 2022

Plasma cells aren't alone!

Brea C. Lipe, MD

GEM-CESAR, ASCENT

ASH 2022

Smouldering myeloma - potentially curable?

Maximilian Merz, MD

Smoldering Myeloma/MGUS - Multilanguage

GEM-CESAR, ASCENT

ASH 2022

Smouldering Myelom – potentiell heilbar?

Maximilian Merz, MD

Mantle Cell Lymphoma

Triangle

ASH 2022

TRIANGLE - addition of Ibrutinib will improve outcome…

Mats Jerkeman, MD

ASH 2022

Fixed-duration Glofitamab produces high quality and…

Ana Marín Niebla, MD

Triangle

ASH 2022

Ibrutinib added in induction and maintenance improves…

Ana Marín Niebla, MD

ASH 2022

Glofitamab in R/R mantle cell lymphoma

Mats Jerkeman, MD

Triangle

ASH 2022

Ibrutinib + Ctx replaces autologous stem cell…

Martin Dreyling, MD

ASH 2022

Glofitamab demonstrates high efficacy in r/r MCL

Toby Eyre, MD

ASH 2022

The R2-Acalabrutinib combination in first-line is…

Ana Marín Niebla, MD

VALERIA

ASH 2022

VALERIA response-adapted treatment for R/R MCL patients

Mats Jerkeman, MD

Tarmac

ASH 2022

Early use of anti-CD19 CAR-T (tisacel) plus ibrutinib…

Ana Marín Niebla, MD

Triangle

ASH 2022

Ibrutinib combined with chemotherapy could replace ASCT

Toby Eyre, MD

Mantle Cell Lymphoma - Multilanguage

Triangle

ASH 2022

Ibrutinib en inducción y mantenimiento mejora la…

Ana Marín Niebla, MD

Triangle

ASH 2022

Ibrutinib + Ctx ersetzt autologe…

Martin Dreyling, MD

ASh 2022

Glofitamab en esquema fijo de 12 meses produce…

Ana Marín Niebla, MD

Triangle

ASH 2022

TRIANGLE- tillägg av ibrutinib förbättrar…

Mats Jerkeman, MD

VALERIA

ASH 2022

Valeria- responsstyrd behandling för recidiverande MCL

Mats Jerkeman, MD

ASH 2022

El triplete R2-Acalabrutinib en primera línea es…

Ana Marín Niebla, MD

ASH 2022

Glofitamab för recidiverande MCL

Mats Jerkeman, MD

Tarmac

ASH 2022

El uso precoz de CAR-T anti-CD19 (tisacel) e ibrutinib…

Ana Marín Niebla, MD

Follicular Lymphoma

Elara Trial

ASH 2022

Tisagenlecleucel at r/r FL: convincing response more…

Martin Dreyling, MD

EPCORE NHL-2 arm 2b

ASH 2022

Epcoritamab - bispecific antibody highly effective in…

Toby Eyre, MD

FLIPI24

ASH 2022

A new FLIPI to predict POD24 in follicular lymphoma

Simone Ferrero, MD

ASH 2022

Watch and Wait remains standard of care

Martin Dreyling, MD

ASH 2022

Is watch & wait still valualble in follicular lymphoma?

Simone Ferrero, MD

ELM-2

ASH 2022

Odronextamab in relapsed/refractory follicular lymphoma

Simone Ferrero, MD

EPCORE NHL-2 arm 2b

ASH 2022

Bispecific antibody Epcoritamab s.c. + R2 convincing

Martin Dreyling, MD

Follicular Lymphoma - Multilanguage

EPCORE NHL-2 arm 2b

ASH 2022

Bispezifischer Antikörper Epcoritamab s.c. + R2…

Martin Dreyling, MD

ASH 2022

Watch and Wait bleibt Standard

Martin Dreyling, MD

EPCORE NHL-2 arm 2b

ASH 2022

Epcoritamab-R2 nel linfoma follicolare…

Simone Ferrero, MD

ELM-2

ASH 2022

Odronextamab nel linfoma follicolare…

Simone Ferrero, MD

Elara Trial

ASH 2022

Tisagenlecleucel beim r/r FL: Überzeugendes Ansprechen…

Martin Dreyling, MD

FLIPI24

ASH 2022

Un nuovo FLIPI per predire la POD24 nel linfoma…

Simone Ferrero, MD

ASH 2022

E' ancora valido il watch & wait nel linfoma…

Simone Ferrero, MD

DLBCL

Alycante

ASH 2022

Two highlight studies in DLBCL treatment

Catherine Thieblemont, MD

Alycante

ASH 2022

Alycante - axi-cel in transplant-ineligible R/R DLBCL…

Mats Jerkeman, MD

DLBCL - Multilanguage

Alycante

ASH 2022

Alycante - axi-cel till patienter med tidigt recidiv av…

Mats Jerkeman, MD

Alycante

ASH 2022

Deux études marquantes dans le traitement du DLBCL

Catherine Thieblemont, MD

Waldenström Macroglobulinemia

ASH 2022

Ventricular arrhythmias under combination ibrutinib +…

Martin Dreyling, MD

Waldenström Macroglobulinemia - Multilanguage

ASH 2022

Ventrikuläre Arrhythmien unter Kombi Ibrutinib +…

Martin Dreyling, MD

Chronic/Small Lymphocytic Leukemia

ALPINE

ASH 2022

Zanubrutinib demonstrates superiority in r/r CLL/SLL

Toby Eyre, MD

BRUIN

ASH 2022

Pirtobrutinib shows activity in pre-treated r/r…

Toby Eyre, MD

Varia

Neutrodiet

ASH 2022

Is it time to feed our patients?

Brea C. Lipe, MD